| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Chorionic Gonadotropin | 30 | 2023 | 78 | 4.180 |
Why?
|
| Menopause | 45 | 2023 | 271 | 3.860 |
Why?
|
| Abortion, Spontaneous | 31 | 2022 | 90 | 3.730 |
Why?
|
| Pregnancy, Ectopic | 33 | 2022 | 51 | 3.620 |
Why?
|
| Pregnancy | 163 | 2024 | 5518 | 3.080 |
Why?
|
| Pregnancy Trimester, First | 24 | 2023 | 125 | 2.340 |
Why?
|
| Fertilization in Vitro | 14 | 2024 | 71 | 2.210 |
Why?
|
| Vaginal Birth after Cesarean | 9 | 2021 | 21 | 1.950 |
Why?
|
| Female | 313 | 2024 | 59511 | 1.780 |
Why?
|
| Pregnancy Rate | 11 | 2022 | 55 | 1.720 |
Why?
|
| Hot Flashes | 21 | 2018 | 72 | 1.710 |
Why?
|
| Adult | 217 | 2024 | 30550 | 1.580 |
Why?
|
| Abortifacient Agents, Nonsteroidal | 10 | 2022 | 19 | 1.550 |
Why?
|
| Depression | 26 | 2023 | 1134 | 1.520 |
Why?
|
| Pregnancy Complications | 18 | 2020 | 429 | 1.490 |
Why?
|
| Postpartum Period | 10 | 2022 | 278 | 1.350 |
Why?
|
| Anti-Mullerian Hormone | 17 | 2022 | 50 | 1.350 |
Why?
|
| Embryo Transfer | 4 | 2024 | 29 | 1.340 |
Why?
|
| Uterine Hemorrhage | 10 | 2023 | 34 | 1.330 |
Why?
|
| Follicle Stimulating Hormone | 29 | 2022 | 216 | 1.290 |
Why?
|
| Premature Birth | 16 | 2016 | 276 | 1.260 |
Why?
|
| Humans | 321 | 2024 | 114689 | 1.260 |
Why?
|
| Cohort Studies | 74 | 2021 | 4895 | 1.240 |
Why?
|
| Estradiol | 27 | 2018 | 455 | 1.230 |
Why?
|
| Pregnancy Outcome | 19 | 2023 | 337 | 1.220 |
Why?
|
| Misoprostol | 5 | 2022 | 18 | 1.170 |
Why?
|
| Pre-Eclampsia | 14 | 2023 | 165 | 1.160 |
Why?
|
| Infertility, Female | 11 | 2019 | 94 | 1.140 |
Why?
|
| Polycystic Ovary Syndrome | 10 | 2020 | 141 | 1.130 |
Why?
|
| Models, Statistical | 9 | 2017 | 599 | 1.090 |
Why?
|
| Methotrexate | 8 | 2021 | 226 | 1.030 |
Why?
|
| Ovary | 11 | 2024 | 191 | 1.030 |
Why?
|
| Cryopreservation | 3 | 2024 | 92 | 1.000 |
Why?
|
| Cesarean Section | 12 | 2020 | 169 | 0.980 |
Why?
|
| Ovarian Reserve | 7 | 2021 | 13 | 0.970 |
Why?
|
| Anxiety | 16 | 2022 | 840 | 0.970 |
Why?
|
| Depressive Disorder, Major | 7 | 2021 | 301 | 0.960 |
Why?
|
| Premenstrual Syndrome | 9 | 2021 | 27 | 0.950 |
Why?
|
| Risk Factors | 69 | 2024 | 8632 | 0.940 |
Why?
|
| Reproductive Techniques, Assisted | 4 | 2018 | 32 | 0.920 |
Why?
|
| Longitudinal Studies | 31 | 2021 | 2387 | 0.920 |
Why?
|
| Reproduction | 8 | 2021 | 178 | 0.910 |
Why?
|
| Embryo Culture Techniques | 1 | 2024 | 12 | 0.900 |
Why?
|
| Inhibins | 14 | 2014 | 45 | 0.870 |
Why?
|
| Young Adult | 75 | 2022 | 10470 | 0.860 |
Why?
|
| Acupuncture Therapy | 2 | 2013 | 18 | 0.850 |
Why?
|
| Aging | 15 | 2024 | 1618 | 0.840 |
Why?
|
| Ultrasonography, Prenatal | 12 | 2021 | 236 | 0.820 |
Why?
|
| Middle Aged | 110 | 2020 | 26737 | 0.810 |
Why?
|
| Multivariate Analysis | 19 | 2020 | 1430 | 0.800 |
Why?
|
| Progesterone | 4 | 2022 | 232 | 0.780 |
Why?
|
| Stress, Psychological | 10 | 2023 | 944 | 0.760 |
Why?
|
| Oxytocics | 3 | 2016 | 15 | 0.740 |
Why?
|
| Prospective Studies | 48 | 2021 | 6220 | 0.740 |
Why?
|
| Labor, Induced | 6 | 2020 | 32 | 0.710 |
Why?
|
| Gestational Age | 18 | 2024 | 760 | 0.710 |
Why?
|
| Sexual and Gender Minorities | 1 | 2023 | 138 | 0.700 |
Why?
|
| Logistic Models | 27 | 2020 | 1841 | 0.690 |
Why?
|
| Hypertension, Pregnancy-Induced | 4 | 2023 | 45 | 0.680 |
Why?
|
| Neoplasms | 13 | 2021 | 2097 | 0.670 |
Why?
|
| Bipolar Disorder | 1 | 2022 | 205 | 0.670 |
Why?
|
| Chorionic Gonadotropin, beta Subunit, Human | 4 | 2015 | 14 | 0.670 |
Why?
|
| Retrospective Studies | 64 | 2024 | 12551 | 0.670 |
Why?
|
| Contraception | 7 | 2022 | 117 | 0.670 |
Why?
|
| Patient Preference | 5 | 2020 | 167 | 0.650 |
Why?
|
| Case-Control Studies | 41 | 2023 | 3003 | 0.630 |
Why?
|
| Odds Ratio | 21 | 2020 | 953 | 0.630 |
Why?
|
| Placental Lactogen | 1 | 2018 | 20 | 0.620 |
Why?
|
| Dehydroepiandrosterone Sulfate | 10 | 2018 | 45 | 0.610 |
Why?
|
| Abortion, Induced | 4 | 2022 | 71 | 0.610 |
Why?
|
| Surveys and Questionnaires | 31 | 2020 | 4623 | 0.610 |
Why?
|
| Patient Acceptance of Health Care | 5 | 2019 | 681 | 0.600 |
Why?
|
| Antineoplastic Agents | 11 | 2021 | 1879 | 0.580 |
Why?
|
| Menstrual Cycle | 7 | 2021 | 108 | 0.570 |
Why?
|
| ADAM Proteins | 2 | 2015 | 58 | 0.570 |
Why?
|
| Primary Ovarian Insufficiency | 5 | 2021 | 30 | 0.560 |
Why?
|
| Sexual Behavior | 5 | 2023 | 440 | 0.560 |
Why?
|
| Cancer Survivors | 5 | 2021 | 205 | 0.560 |
Why?
|
| Biomarkers | 29 | 2023 | 3408 | 0.540 |
Why?
|
| Ovulation Induction | 5 | 2022 | 49 | 0.540 |
Why?
|
| Uterine Neoplasms | 4 | 2018 | 73 | 0.520 |
Why?
|
| Risk Assessment | 19 | 2024 | 2968 | 0.520 |
Why?
|
| Executive Function | 8 | 2023 | 380 | 0.510 |
Why?
|
| Time Factors | 27 | 2024 | 6116 | 0.510 |
Why?
|
| Child Abuse, Sexual | 3 | 2017 | 81 | 0.510 |
Why?
|
| Smoking | 10 | 2022 | 1383 | 0.510 |
Why?
|
| Depressive Disorder | 5 | 2017 | 332 | 0.500 |
Why?
|
| Abortion, Incomplete | 1 | 2015 | 1 | 0.490 |
Why?
|
| Abortion, Missed | 1 | 2015 | 1 | 0.490 |
Why?
|
| Predictive Value of Tests | 21 | 2018 | 1796 | 0.490 |
Why?
|
| Pennsylvania | 16 | 2019 | 94 | 0.480 |
Why?
|
| Bayes Theorem | 3 | 2015 | 329 | 0.480 |
Why?
|
| Breast Neoplasms | 10 | 2017 | 1862 | 0.480 |
Why?
|
| Pregnancy Trimester, Second | 4 | 2019 | 66 | 0.470 |
Why?
|
| Body Mass Index | 18 | 2020 | 1959 | 0.470 |
Why?
|
| Fetal Membranes, Premature Rupture | 7 | 2009 | 34 | 0.450 |
Why?
|
| Embryo Implantation | 2 | 2022 | 23 | 0.440 |
Why?
|
| Faculty, Medical | 4 | 2021 | 228 | 0.440 |
Why?
|
| Sensitivity and Specificity | 14 | 2020 | 1693 | 0.440 |
Why?
|
| Perimenopause | 7 | 2023 | 61 | 0.440 |
Why?
|
| Environmental Exposure | 1 | 2017 | 372 | 0.430 |
Why?
|
| Cross-Sectional Studies | 27 | 2023 | 4410 | 0.430 |
Why?
|
| Trial of Labor | 5 | 2021 | 14 | 0.430 |
Why?
|
| Leiomyoma | 3 | 2018 | 44 | 0.430 |
Why?
|
| Sexual Dysfunction, Physiological | 4 | 2018 | 60 | 0.420 |
Why?
|
| Luteinizing Hormone | 12 | 2018 | 169 | 0.420 |
Why?
|
| Infertility | 3 | 2024 | 45 | 0.410 |
Why?
|
| Philadelphia | 16 | 2019 | 46 | 0.410 |
Why?
|
| Premenopause | 7 | 2023 | 106 | 0.410 |
Why?
|
| Randomized Controlled Trials as Topic | 8 | 2020 | 1214 | 0.410 |
Why?
|
| Urban Population | 9 | 2017 | 397 | 0.410 |
Why?
|
| Labor Stage, First | 3 | 2017 | 4 | 0.410 |
Why?
|
| Physicians, Women | 3 | 2021 | 55 | 0.410 |
Why?
|
| Parturition | 3 | 2021 | 54 | 0.400 |
Why?
|
| Infant, Newborn | 20 | 2024 | 5047 | 0.400 |
Why?
|
| Libido | 7 | 2023 | 24 | 0.400 |
Why?
|
| Adolescent | 44 | 2022 | 17848 | 0.400 |
Why?
|
| Ovarian Neoplasms | 4 | 2020 | 388 | 0.390 |
Why?
|
| Membrane Proteins | 3 | 2015 | 1019 | 0.390 |
Why?
|
| Cognition | 8 | 2023 | 989 | 0.390 |
Why?
|
| Age Factors | 22 | 2020 | 2894 | 0.390 |
Why?
|
| Follow-Up Studies | 23 | 2022 | 4411 | 0.390 |
Why?
|
| Linear Models | 12 | 2019 | 768 | 0.380 |
Why?
|
| Latin America | 2 | 2021 | 69 | 0.380 |
Why?
|
| Polymorphism, Single Nucleotide | 11 | 2017 | 1880 | 0.370 |
Why?
|
| Obstetric Labor, Premature | 5 | 2013 | 33 | 0.370 |
Why?
|
| Fertility Preservation | 4 | 2016 | 46 | 0.370 |
Why?
|
| World Health Organization | 2 | 2021 | 102 | 0.370 |
Why?
|
| Obstetric Labor Complications | 4 | 2020 | 30 | 0.370 |
Why?
|
| Abortifacient Agents, Steroidal | 2 | 2021 | 4 | 0.360 |
Why?
|
| Sleep Initiation and Maintenance Disorders | 3 | 2023 | 119 | 0.360 |
Why?
|
| Survivors | 6 | 2014 | 411 | 0.360 |
Why?
|
| Hormone Replacement Therapy | 1 | 2011 | 77 | 0.360 |
Why?
|
| Substance Withdrawal Syndrome | 2 | 2022 | 159 | 0.350 |
Why?
|
| Sleep Wake Disorders | 3 | 2023 | 233 | 0.350 |
Why?
|
| Delivery, Obstetric | 7 | 2019 | 118 | 0.350 |
Why?
|
| Watchful Waiting | 2 | 2021 | 55 | 0.340 |
Why?
|
| Data Interpretation, Statistical | 4 | 2012 | 321 | 0.340 |
Why?
|
| Ovarian Follicle | 6 | 2024 | 61 | 0.330 |
Why?
|
| Fetal Macrosomia | 2 | 2024 | 58 | 0.330 |
Why?
|
| Obesity | 8 | 2019 | 2508 | 0.330 |
Why?
|
| Hypothalamo-Hypophyseal System | 4 | 2023 | 164 | 0.330 |
Why?
|
| Biometry | 3 | 2015 | 62 | 0.320 |
Why?
|
| Cell-Free Nucleic Acids | 2 | 2020 | 26 | 0.320 |
Why?
|
| Severity of Illness Index | 14 | 2019 | 2540 | 0.320 |
Why?
|
| Dilatation and Curettage | 4 | 2021 | 10 | 0.310 |
Why?
|
| Promoter Regions, Genetic | 9 | 2009 | 1131 | 0.310 |
Why?
|
| Socioeconomic Factors | 15 | 2017 | 1078 | 0.310 |
Why?
|
| Treatment Outcome | 25 | 2022 | 9088 | 0.310 |
Why?
|
| Fecal Incontinence | 4 | 2020 | 73 | 0.310 |
Why?
|
| Postmenopause | 5 | 2023 | 303 | 0.300 |
Why?
|
| Tryptophan | 3 | 2020 | 136 | 0.300 |
Why?
|
| Intrauterine Devices, Copper | 2 | 2018 | 7 | 0.300 |
Why?
|
| Intrauterine Device Expulsion | 2 | 2018 | 6 | 0.300 |
Why?
|
| Uterine Myomectomy | 2 | 2018 | 4 | 0.300 |
Why?
|
| Oocyte Retrieval | 3 | 2017 | 11 | 0.300 |
Why?
|
| Reference Values | 9 | 2020 | 743 | 0.300 |
Why?
|
| Endometriosis | 4 | 2016 | 40 | 0.290 |
Why?
|
| Metabolic Syndrome | 4 | 2013 | 321 | 0.290 |
Why?
|
| Factor Analysis, Statistical | 4 | 2017 | 257 | 0.290 |
Why?
|
| Follicle Stimulating Hormone, Human | 4 | 2022 | 11 | 0.290 |
Why?
|
| Testosterone | 13 | 2018 | 343 | 0.290 |
Why?
|
| ADAM12 Protein | 3 | 2016 | 4 | 0.280 |
Why?
|
| Vascular Endothelial Growth Factor Receptor-1 | 3 | 2020 | 66 | 0.280 |
Why?
|
| Gonadal Steroid Hormones | 6 | 2012 | 124 | 0.280 |
Why?
|
| Prevalence | 15 | 2020 | 2251 | 0.280 |
Why?
|
| Pituitary-Adrenal System | 3 | 2019 | 130 | 0.280 |
Why?
|
| Minimally Invasive Surgical Procedures | 2 | 2019 | 154 | 0.280 |
Why?
|
| Temperament | 2 | 2017 | 46 | 0.280 |
Why?
|
| Uterus | 5 | 2022 | 192 | 0.280 |
Why?
|
| Urinary Incontinence | 5 | 2017 | 56 | 0.270 |
Why?
|
| Memory, Short-Term | 3 | 2020 | 225 | 0.270 |
Why?
|
| Mifepristone | 3 | 2022 | 60 | 0.270 |
Why?
|
| Maternal Behavior | 2 | 2017 | 70 | 0.270 |
Why?
|
| Weight Gain | 3 | 2016 | 453 | 0.270 |
Why?
|
| Anticoagulants | 2 | 2023 | 550 | 0.270 |
Why?
|
| Dogs | 2 | 2017 | 334 | 0.270 |
Why?
|
| Hormones | 5 | 2005 | 132 | 0.260 |
Why?
|
| Ultrasonography | 9 | 2020 | 634 | 0.260 |
Why?
|
| Life Change Events | 2 | 2017 | 135 | 0.260 |
Why?
|
| Infant, Small for Gestational Age | 3 | 2016 | 76 | 0.260 |
Why?
|
| Prognosis | 13 | 2021 | 3329 | 0.260 |
Why?
|
| Career Mobility | 3 | 2017 | 61 | 0.260 |
Why?
|
| Models, Biological | 3 | 2021 | 1621 | 0.260 |
Why?
|
| Postnatal Care | 2 | 2018 | 65 | 0.260 |
Why?
|
| Stress Disorders, Post-Traumatic | 3 | 2017 | 758 | 0.250 |
Why?
|
| Therapy, Computer-Assisted | 2 | 2017 | 58 | 0.250 |
Why?
|
| Periodontal Diseases | 3 | 2010 | 57 | 0.250 |
Why?
|
| Child Abuse | 3 | 2020 | 456 | 0.240 |
Why?
|
| Fetus | 4 | 2023 | 700 | 0.240 |
Why?
|
| Prenatal Care | 8 | 2019 | 253 | 0.240 |
Why?
|
| Transcranial Magnetic Stimulation | 2 | 2018 | 44 | 0.240 |
Why?
|
| Recovery of Function | 4 | 2021 | 574 | 0.240 |
Why?
|
| Operative Time | 3 | 2020 | 106 | 0.240 |
Why?
|
| Androgens | 2 | 2019 | 167 | 0.240 |
Why?
|
| Proportional Hazards Models | 9 | 2019 | 1075 | 0.240 |
Why?
|
| Achievement | 2 | 2017 | 54 | 0.240 |
Why?
|
| Patient Satisfaction | 7 | 2021 | 578 | 0.240 |
Why?
|
| Birth Weight | 3 | 2024 | 440 | 0.240 |
Why?
|
| C-Reactive Protein | 3 | 2023 | 362 | 0.240 |
Why?
|
| Live Birth | 2 | 2022 | 48 | 0.240 |
Why?
|
| Pelvic Organ Prolapse | 3 | 2021 | 39 | 0.240 |
Why?
|
| Fetal Diseases | 1 | 2005 | 147 | 0.230 |
Why?
|
| Genes, BRCA2 | 2 | 2016 | 24 | 0.230 |
Why?
|
| Brain Diseases | 1 | 2005 | 125 | 0.230 |
Why?
|
| Ovulation | 2 | 2016 | 39 | 0.230 |
Why?
|
| Cardiovascular Diseases | 4 | 2020 | 1727 | 0.230 |
Why?
|
| Clinical Trials as Topic | 4 | 2012 | 932 | 0.230 |
Why?
|
| Genes, BRCA1 | 2 | 2016 | 31 | 0.230 |
Why?
|
| Dairying | 2 | 2014 | 7 | 0.230 |
Why?
|
| Quality of Life | 6 | 2018 | 2353 | 0.230 |
Why?
|
| Pregnancy Tests | 2 | 2018 | 7 | 0.230 |
Why?
|
| Imaging, Three-Dimensional | 3 | 2016 | 512 | 0.230 |
Why?
|
| Diabetes, Gestational | 2 | 2020 | 281 | 0.230 |
Why?
|
| Academic Medical Centers | 2 | 2021 | 411 | 0.230 |
Why?
|
| Sertraline | 3 | 2021 | 26 | 0.230 |
Why?
|
| Pelvic Pain | 3 | 2016 | 32 | 0.230 |
Why?
|
| Cervix Uteri | 3 | 2019 | 45 | 0.220 |
Why?
|
| Trophoblasts | 2 | 2022 | 163 | 0.220 |
Why?
|
| Schools, Medical | 3 | 2017 | 120 | 0.220 |
Why?
|
| Sterilization, Tubal | 2 | 2019 | 12 | 0.220 |
Why?
|
| Endometrial Neoplasms | 2 | 2017 | 141 | 0.220 |
Why?
|
| HELLP Syndrome | 1 | 2023 | 6 | 0.220 |
Why?
|
| United States | 15 | 2023 | 12183 | 0.220 |
Why?
|
| Parity | 3 | 2020 | 98 | 0.220 |
Why?
|
| Placenta | 4 | 2016 | 626 | 0.220 |
Why?
|
| Reproducibility of Results | 13 | 2023 | 2765 | 0.220 |
Why?
|
| Double-Blind Method | 11 | 2020 | 1660 | 0.220 |
Why?
|
| Hydrocortisone | 4 | 2019 | 267 | 0.210 |
Why?
|
| Decision Support Techniques | 2 | 2017 | 355 | 0.210 |
Why?
|
| Heterosexuality | 1 | 2023 | 29 | 0.210 |
Why?
|
| Contraception Behavior | 3 | 2020 | 81 | 0.210 |
Why?
|
| Choice Behavior | 3 | 2018 | 155 | 0.200 |
Why?
|
| Intrauterine Devices | 2 | 2019 | 24 | 0.200 |
Why?
|
| Reflex, Startle | 1 | 2022 | 57 | 0.200 |
Why?
|
| Cognition Disorders | 3 | 2017 | 476 | 0.200 |
Why?
|
| Fetal Viability | 1 | 2022 | 3 | 0.200 |
Why?
|
| Infant, Premature | 8 | 2010 | 476 | 0.200 |
Why?
|
| Cross-Over Studies | 6 | 2022 | 440 | 0.200 |
Why?
|
| Cerebrospinal Fluid Rhinorrhea | 1 | 2022 | 7 | 0.200 |
Why?
|
| Cytochrome P-450 Enzyme System | 2 | 2014 | 108 | 0.200 |
Why?
|
| Decidua | 1 | 2022 | 23 | 0.200 |
Why?
|
| Pregnancy Complications, Cardiovascular | 2 | 2016 | 64 | 0.200 |
Why?
|
| Risk-Taking | 1 | 2005 | 333 | 0.200 |
Why?
|
| Postoperative Complications | 4 | 2020 | 2128 | 0.200 |
Why?
|
| Cytokines | 4 | 2019 | 1841 | 0.200 |
Why?
|
| Likelihood Functions | 4 | 2017 | 126 | 0.190 |
Why?
|
| Minority Groups | 2 | 2021 | 227 | 0.190 |
Why?
|
| Glycodelin | 2 | 2023 | 2 | 0.190 |
Why?
|
| Pain | 4 | 2020 | 705 | 0.190 |
Why?
|
| Anti-Bacterial Agents | 4 | 2014 | 1481 | 0.190 |
Why?
|
| Premenstrual Dysphoric Disorder | 1 | 2021 | 16 | 0.190 |
Why?
|
| Male | 36 | 2023 | 55599 | 0.190 |
Why?
|
| Aged | 22 | 2021 | 19074 | 0.190 |
Why?
|
| Smartphone | 2 | 2019 | 73 | 0.190 |
Why?
|
| Postpartum Hemorrhage | 2 | 2019 | 14 | 0.190 |
Why?
|
| Drug Administration Schedule | 7 | 2010 | 718 | 0.190 |
Why?
|
| Perioperative Period | 2 | 2018 | 49 | 0.180 |
Why?
|
| Cattle | 2 | 2014 | 920 | 0.180 |
Why?
|
| Endocrine Glands | 1 | 2021 | 15 | 0.180 |
Why?
|
| Hospitals, University | 3 | 2016 | 172 | 0.180 |
Why?
|
| Gonadotropins | 4 | 2015 | 37 | 0.180 |
Why?
|
| BRCA2 Protein | 2 | 2020 | 41 | 0.180 |
Why?
|
| Pelvic Floor Disorders | 2 | 2019 | 9 | 0.180 |
Why?
|
| Fertilization | 2 | 2013 | 41 | 0.180 |
Why?
|
| Reproductive Behavior | 2 | 2020 | 10 | 0.180 |
Why?
|
| Citalopram | 3 | 2014 | 27 | 0.180 |
Why?
|
| Hysterectomy | 2 | 2020 | 106 | 0.180 |
Why?
|
| Exercise | 4 | 2017 | 1644 | 0.180 |
Why?
|
| Patient Compliance | 4 | 2019 | 525 | 0.180 |
Why?
|
| Genital Diseases, Female | 1 | 2020 | 25 | 0.180 |
Why?
|
| Sweating | 2 | 2018 | 23 | 0.180 |
Why?
|
| Manometry | 1 | 2020 | 89 | 0.180 |
Why?
|
| Patient Positioning | 1 | 2020 | 42 | 0.180 |
Why?
|
| Rh Isoimmunization | 1 | 2020 | 3 | 0.170 |
Why?
|
| Diagnosis, Differential | 6 | 2018 | 1342 | 0.170 |
Why?
|
| Oxycodone | 1 | 2020 | 44 | 0.170 |
Why?
|
| Tobacco Use Disorder | 1 | 2022 | 234 | 0.170 |
Why?
|
| Puerperal Disorders | 1 | 2020 | 30 | 0.170 |
Why?
|
| ROC Curve | 4 | 2016 | 442 | 0.170 |
Why?
|
| Nerve Net | 2 | 2020 | 226 | 0.170 |
Why?
|
| Uncertainty | 1 | 2020 | 95 | 0.170 |
Why?
|
| Tertiary Care Centers | 3 | 2019 | 126 | 0.170 |
Why?
|
| Fetomaternal Transfusion | 1 | 2020 | 10 | 0.170 |
Why?
|
| Regression Analysis | 9 | 2015 | 945 | 0.170 |
Why?
|
| Vagina | 2 | 2019 | 146 | 0.170 |
Why?
|
| Text Messaging | 2 | 2019 | 152 | 0.170 |
Why?
|
| Lactobacillus | 1 | 2019 | 24 | 0.170 |
Why?
|
| Pregnancy, Unplanned | 1 | 2020 | 33 | 0.170 |
Why?
|
| Proteome | 2 | 2022 | 339 | 0.170 |
Why?
|
| Hypogonadism | 1 | 2020 | 75 | 0.170 |
Why?
|
| Healthcare Disparities | 3 | 2021 | 480 | 0.170 |
Why?
|
| Term Birth | 3 | 2016 | 19 | 0.170 |
Why?
|
| Health Services Accessibility | 4 | 2020 | 763 | 0.170 |
Why?
|
| Hysterosalpingography | 2 | 2014 | 6 | 0.170 |
Why?
|
| Pain, Procedural | 1 | 2019 | 12 | 0.170 |
Why?
|
| Platelet Aggregation Inhibitors | 1 | 2023 | 401 | 0.170 |
Why?
|
| Levonorgestrel | 1 | 2019 | 31 | 0.160 |
Why?
|
| Psychiatric Status Rating Scales | 8 | 2017 | 482 | 0.160 |
Why?
|
| Lower Urinary Tract Symptoms | 1 | 2020 | 47 | 0.160 |
Why?
|
| Algorithms | 7 | 2019 | 1469 | 0.160 |
Why?
|
| Family Planning Services | 1 | 2020 | 68 | 0.160 |
Why?
|
| Career Choice | 1 | 2021 | 177 | 0.160 |
Why?
|
| Telecommunications | 1 | 2019 | 16 | 0.160 |
Why?
|
| Pain Perception | 1 | 2019 | 37 | 0.160 |
Why?
|
| Congenital Abnormalities | 1 | 1999 | 73 | 0.160 |
Why?
|
| Fetal Growth Retardation | 7 | 2013 | 467 | 0.160 |
Why?
|
| Infant Formula | 1 | 2019 | 74 | 0.160 |
Why?
|
| Uterine Rupture | 4 | 2006 | 7 | 0.160 |
Why?
|
| Body Image | 1 | 2019 | 68 | 0.160 |
Why?
|
| Smoking Cessation | 1 | 2022 | 374 | 0.160 |
Why?
|
| Depression, Postpartum | 1 | 2020 | 103 | 0.160 |
Why?
|
| Waiting Lists | 1 | 2020 | 211 | 0.160 |
Why?
|
| Comorbidity | 7 | 2018 | 1448 | 0.160 |
Why?
|
| Blood Pressure Monitoring, Ambulatory | 1 | 2019 | 61 | 0.160 |
Why?
|
| Infant, Premature, Diseases | 2 | 2010 | 89 | 0.160 |
Why?
|
| Research Design | 3 | 2014 | 928 | 0.150 |
Why?
|
| Intrauterine Device Migration | 1 | 2018 | 3 | 0.150 |
Why?
|
| Terminology as Topic | 3 | 2019 | 187 | 0.150 |
Why?
|
| Consumer Health Information | 1 | 2019 | 47 | 0.150 |
Why?
|
| Feeding Behavior | 2 | 2017 | 574 | 0.150 |
Why?
|
| Angioplasty, Balloon, Coronary | 1 | 1999 | 146 | 0.150 |
Why?
|
| Antineoplastic Agents, Alkylating | 2 | 2016 | 68 | 0.150 |
Why?
|
| Outpatient Clinics, Hospital | 1 | 2019 | 79 | 0.150 |
Why?
|
| Pregnancy-Associated Plasma Protein-A | 2 | 2016 | 14 | 0.150 |
Why?
|
| Risk Reduction Behavior | 2 | 2018 | 201 | 0.150 |
Why?
|
| Interleukin-6 | 4 | 2023 | 676 | 0.150 |
Why?
|
| Postoperative Hemorrhage | 1 | 2019 | 74 | 0.150 |
Why?
|
| Kisspeptins | 1 | 2018 | 5 | 0.150 |
Why?
|
| Education, Medical | 1 | 2021 | 215 | 0.150 |
Why?
|
| Longevity | 1 | 2019 | 137 | 0.150 |
Why?
|
| Climacteric | 3 | 2008 | 4 | 0.150 |
Why?
|
| Spermatocidal Agents | 2 | 2015 | 5 | 0.150 |
Why?
|
| Mental Health | 2 | 2021 | 562 | 0.150 |
Why?
|
| Infant, Low Birth Weight | 2 | 2016 | 125 | 0.150 |
Why?
|
| Maternal Serum Screening Tests | 1 | 2017 | 3 | 0.150 |
Why?
|
| Communication Barriers | 1 | 2019 | 89 | 0.150 |
Why?
|
| Oxytocin | 2 | 2016 | 45 | 0.150 |
Why?
|
| Internet | 2 | 2019 | 596 | 0.150 |
Why?
|
| Poisson Distribution | 3 | 2012 | 71 | 0.150 |
Why?
|
| Cluster Analysis | 1 | 1999 | 455 | 0.150 |
Why?
|
| Estrone | 2 | 2016 | 35 | 0.150 |
Why?
|
| Urinalysis | 2 | 2016 | 64 | 0.150 |
Why?
|
| Anticonvulsants | 4 | 2001 | 179 | 0.150 |
Why?
|
| Contraceptive Agents, Female | 2 | 2018 | 64 | 0.140 |
Why?
|
| Time-to-Treatment | 1 | 2019 | 147 | 0.140 |
Why?
|
| Morcellation | 1 | 2017 | 1 | 0.140 |
Why?
|
| Mortality | 1 | 2019 | 287 | 0.140 |
Why?
|
| Vascular Calcification | 1 | 2019 | 107 | 0.140 |
Why?
|
| HSP47 Heat-Shock Proteins | 2 | 2008 | 4 | 0.140 |
Why?
|
| Immunoassay | 2 | 2016 | 95 | 0.140 |
Why?
|
| Information Storage and Retrieval | 1 | 2018 | 106 | 0.140 |
Why?
|
| Administration, Intravaginal | 2 | 2015 | 20 | 0.140 |
Why?
|
| Coronary Vessels | 1 | 2019 | 227 | 0.140 |
Why?
|
| Blood | 1 | 2017 | 96 | 0.140 |
Why?
|
| Lead Poisoning | 1 | 2017 | 17 | 0.140 |
Why?
|
| Enoxaparin | 1 | 2017 | 52 | 0.140 |
Why?
|
| Attitude to Health | 4 | 2016 | 406 | 0.140 |
Why?
|
| Feeding and Eating Disorders | 1 | 2018 | 103 | 0.140 |
Why?
|
| Binge-Eating Disorder | 1 | 2017 | 10 | 0.140 |
Why?
|
| Pregnancy Complications, Infectious | 4 | 2010 | 288 | 0.140 |
Why?
|
| Decision Making | 3 | 2020 | 782 | 0.140 |
Why?
|
| Pregnant Women | 2 | 2020 | 131 | 0.140 |
Why?
|
| Vitamin D Deficiency | 1 | 2019 | 158 | 0.140 |
Why?
|
| Obesity, Morbid | 1 | 2020 | 197 | 0.140 |
Why?
|
| Bulimia Nervosa | 1 | 2017 | 19 | 0.140 |
Why?
|
| Activins | 1 | 2016 | 26 | 0.140 |
Why?
|
| Doulas | 1 | 2016 | 2 | 0.140 |
Why?
|
| Vacuum Curettage | 1 | 2016 | 5 | 0.140 |
Why?
|
| Pregnanediol | 1 | 2016 | 12 | 0.140 |
Why?
|
| Motor Activity | 2 | 2014 | 640 | 0.140 |
Why?
|
| Glucuronides | 1 | 2016 | 12 | 0.140 |
Why?
|
| Laparoscopy | 2 | 2018 | 398 | 0.140 |
Why?
|
| Follicular Phase | 2 | 2008 | 36 | 0.140 |
Why?
|
| Adult Survivors of Child Adverse Events | 1 | 2016 | 10 | 0.140 |
Why?
|
| Data Collection | 3 | 2014 | 620 | 0.140 |
Why?
|
| Pregnancy, Tubal | 1 | 2016 | 5 | 0.140 |
Why?
|
| Women's Health | 3 | 2017 | 271 | 0.130 |
Why?
|
| Pregnanolone | 2 | 2022 | 20 | 0.130 |
Why?
|
| Desogestrel | 2 | 2014 | 40 | 0.130 |
Why?
|
| Fetal Monitoring | 2 | 2014 | 16 | 0.130 |
Why?
|
| Adrenal Glands | 1 | 2016 | 66 | 0.130 |
Why?
|
| Fertility | 2 | 2016 | 130 | 0.130 |
Why?
|
| Body Composition | 2 | 2013 | 590 | 0.130 |
Why?
|
| Problem Solving | 1 | 2017 | 141 | 0.130 |
Why?
|
| Healthy Lifestyle | 1 | 2016 | 30 | 0.130 |
Why?
|
| Smell | 2 | 2015 | 111 | 0.130 |
Why?
|
| Breast Feeding | 1 | 2019 | 368 | 0.130 |
Why?
|
| Cesarean Section, Repeat | 2 | 2006 | 9 | 0.130 |
Why?
|
| Stress, Physiological | 1 | 2019 | 378 | 0.130 |
Why?
|
| Robotic Surgical Procedures | 1 | 2017 | 85 | 0.130 |
Why?
|
| Catheterization | 1 | 2016 | 159 | 0.130 |
Why?
|
| Urinary Bladder, Overactive | 1 | 2016 | 20 | 0.130 |
Why?
|
| Amnion | 4 | 2008 | 24 | 0.130 |
Why?
|
| Clinical Protocols | 2 | 2014 | 233 | 0.130 |
Why?
|
| Ventricular Dysfunction, Left | 1 | 2019 | 358 | 0.130 |
Why?
|
| Health Surveys | 5 | 2011 | 443 | 0.130 |
Why?
|
| Cigarette Smoking | 1 | 2017 | 74 | 0.130 |
Why?
|
| Brain | 4 | 2020 | 2371 | 0.130 |
Why?
|
| Aged, 80 and over | 10 | 2021 | 6347 | 0.130 |
Why?
|
| Pilot Projects | 6 | 2020 | 1373 | 0.130 |
Why?
|
| Psychotherapy | 1 | 2017 | 149 | 0.130 |
Why?
|
| Lisdexamfetamine Dimesylate | 1 | 2015 | 4 | 0.130 |
Why?
|
| Computer Simulation | 4 | 2015 | 873 | 0.130 |
Why?
|
| Signal Transduction | 2 | 2022 | 4513 | 0.120 |
Why?
|
| Sexual Dysfunctions, Psychological | 2 | 2007 | 31 | 0.120 |
Why?
|
| Drug Utilization | 2 | 2014 | 167 | 0.120 |
Why?
|
| Matrix Metalloproteinase 1 | 2 | 2008 | 20 | 0.120 |
Why?
|
| Gynecologic Surgical Procedures | 1 | 2015 | 44 | 0.120 |
Why?
|
| Area Under Curve | 4 | 2018 | 274 | 0.120 |
Why?
|
| Prenatal Exposure Delayed Effects | 2 | 2017 | 452 | 0.120 |
Why?
|
| Nocturia | 2 | 2020 | 7 | 0.120 |
Why?
|
| Child | 11 | 2020 | 18415 | 0.120 |
Why?
|
| Fertility Agents, Female | 2 | 2012 | 19 | 0.120 |
Why?
|
| Mobile Applications | 1 | 2017 | 141 | 0.120 |
Why?
|
| Tablets | 1 | 2015 | 36 | 0.120 |
Why?
|
| Catechol O-Methyltransferase | 2 | 2012 | 17 | 0.120 |
Why?
|
| Neuropsychological Tests | 5 | 2020 | 927 | 0.120 |
Why?
|
| Environment | 2 | 2014 | 332 | 0.120 |
Why?
|
| Memory | 2 | 2013 | 211 | 0.120 |
Why?
|
| Abdominal Pain | 1 | 2016 | 135 | 0.120 |
Why?
|
| Labor Stage, Second | 1 | 2014 | 3 | 0.120 |
Why?
|
| Body Size | 3 | 2014 | 92 | 0.120 |
Why?
|
| Incidence | 9 | 2017 | 2313 | 0.120 |
Why?
|
| Milk | 2 | 2014 | 124 | 0.120 |
Why?
|
| Aryl Hydrocarbon Hydroxylases | 2 | 2012 | 41 | 0.120 |
Why?
|
| Dystocia | 1 | 2014 | 9 | 0.120 |
Why?
|
| Dose-Response Relationship, Drug | 6 | 2019 | 1842 | 0.120 |
Why?
|
| Drug Residues | 1 | 2014 | 5 | 0.120 |
Why?
|
| Dehydroepiandrosterone | 3 | 2005 | 49 | 0.120 |
Why?
|
| Chorioamnionitis | 3 | 2014 | 36 | 0.120 |
Why?
|
| Placentation | 1 | 2014 | 40 | 0.120 |
Why?
|
| Benzocaine | 1 | 2014 | 1 | 0.120 |
Why?
|
| Contraceptives, Oral, Hormonal | 1 | 2014 | 23 | 0.120 |
Why?
|
| Endometrial Ablation Techniques | 1 | 2014 | 2 | 0.120 |
Why?
|
| Food Contamination | 1 | 2014 | 43 | 0.110 |
Why?
|
| Job Satisfaction | 2 | 2012 | 168 | 0.110 |
Why?
|
| Uterine Diseases | 3 | 2009 | 14 | 0.110 |
Why?
|
| Peru | 4 | 2014 | 54 | 0.110 |
Why?
|
| Estrogen Replacement Therapy | 1 | 2015 | 116 | 0.110 |
Why?
|
| Referral and Consultation | 1 | 2019 | 635 | 0.110 |
Why?
|
| Medical Records | 3 | 2010 | 153 | 0.110 |
Why?
|
| Multicenter Studies as Topic | 3 | 2019 | 249 | 0.110 |
Why?
|
| Carcinoma, Lobular | 1 | 2014 | 44 | 0.110 |
Why?
|
| Menorrhagia | 1 | 2014 | 14 | 0.110 |
Why?
|
| Proteinuria | 1 | 2014 | 77 | 0.110 |
Why?
|
| Leadership | 1 | 2017 | 292 | 0.110 |
Why?
|
| Pregnancy Proteins | 1 | 2014 | 36 | 0.110 |
Why?
|
| Patient Education as Topic | 2 | 2016 | 680 | 0.110 |
Why?
|
| Animal Husbandry | 1 | 2014 | 33 | 0.110 |
Why?
|
| Carcinoma, Ductal, Breast | 1 | 2014 | 76 | 0.110 |
Why?
|
| Health Care Costs | 1 | 2017 | 381 | 0.110 |
Why?
|
| Central Nervous System Stimulants | 1 | 2015 | 139 | 0.110 |
Why?
|
| Blood Pressure | 1 | 2020 | 1538 | 0.110 |
Why?
|
| Weight Loss | 1 | 2018 | 642 | 0.110 |
Why?
|
| Pain Management | 1 | 2016 | 288 | 0.110 |
Why?
|
| Sperm Injections, Intracytoplasmic | 1 | 2013 | 7 | 0.110 |
Why?
|
| Biomarkers, Tumor | 2 | 2017 | 1040 | 0.110 |
Why?
|
| Health Status | 3 | 2011 | 722 | 0.110 |
Why?
|
| Analgesics, Opioid | 1 | 2020 | 771 | 0.110 |
Why?
|
| Betamethasone | 2 | 2010 | 19 | 0.110 |
Why?
|
| Communication | 1 | 2019 | 744 | 0.110 |
Why?
|
| Calcium | 1 | 2019 | 1108 | 0.110 |
Why?
|
| Matrix Metalloproteinase 8 | 2 | 2004 | 9 | 0.110 |
Why?
|
| Proteomics | 3 | 2011 | 836 | 0.110 |
Why?
|
| Emergency Service, Hospital | 3 | 2021 | 1815 | 0.110 |
Why?
|
| Hematologic Diseases | 1 | 2013 | 55 | 0.110 |
Why?
|
| Device Removal | 1 | 2014 | 126 | 0.110 |
Why?
|
| Taxoids | 1 | 2013 | 93 | 0.100 |
Why?
|
| Spermatozoa | 2 | 2011 | 84 | 0.100 |
Why?
|
| Child Development | 1 | 2017 | 385 | 0.100 |
Why?
|
| BCG Vaccine | 1 | 2012 | 18 | 0.100 |
Why?
|
| Headache | 2 | 2018 | 133 | 0.100 |
Why?
|
| Cystitis, Interstitial | 1 | 2012 | 16 | 0.100 |
Why?
|
| Memory Disorders | 1 | 2013 | 155 | 0.100 |
Why?
|
| Personnel Turnover | 1 | 2012 | 27 | 0.100 |
Why?
|
| Telemedicine | 2 | 2019 | 662 | 0.100 |
Why?
|
| Creatinine | 1 | 2014 | 425 | 0.100 |
Why?
|
| Sperm Motility | 3 | 2009 | 26 | 0.100 |
Why?
|
| Cytochrome P-450 CYP1A2 | 1 | 2012 | 2 | 0.100 |
Why?
|
| Social Class | 2 | 2010 | 204 | 0.100 |
Why?
|
| Databases, Factual | 5 | 2017 | 1125 | 0.100 |
Why?
|
| Gastrointestinal Microbiome | 1 | 2018 | 501 | 0.100 |
Why?
|
| Residence Characteristics | 1 | 2014 | 275 | 0.100 |
Why?
|
| Organizational Policy | 1 | 2012 | 68 | 0.100 |
Why?
|
| Nitriles | 1 | 2013 | 149 | 0.100 |
Why?
|
| Monte Carlo Method | 1 | 2012 | 138 | 0.100 |
Why?
|
| Paclitaxel | 1 | 2013 | 190 | 0.100 |
Why?
|
| Peripheral Nervous System Diseases | 1 | 2013 | 120 | 0.100 |
Why?
|
| Elasticity Imaging Techniques | 1 | 2012 | 40 | 0.100 |
Why?
|
| Genetic Variation | 3 | 2014 | 870 | 0.100 |
Why?
|
| Chemistry, Clinical | 1 | 2012 | 11 | 0.100 |
Why?
|
| Attention | 1 | 2015 | 393 | 0.100 |
Why?
|
| Morbidity | 4 | 2018 | 280 | 0.100 |
Why?
|
| Mood Disorders | 3 | 2020 | 112 | 0.100 |
Why?
|
| Gravidity | 1 | 2011 | 7 | 0.100 |
Why?
|
| Venous Thromboembolism | 1 | 2015 | 231 | 0.100 |
Why?
|
| Smokers | 2 | 2022 | 129 | 0.100 |
Why?
|
| Factor V | 2 | 2009 | 22 | 0.100 |
Why?
|
| Thyroid Hormones | 1 | 2012 | 53 | 0.100 |
Why?
|
| Labor Pain | 2 | 2009 | 8 | 0.100 |
Why?
|
| Triazoles | 1 | 2013 | 131 | 0.100 |
Why?
|
| Validation Studies as Topic | 1 | 2011 | 23 | 0.100 |
Why?
|
| Hypothyroidism | 1 | 2012 | 64 | 0.100 |
Why?
|
| Insemination, Artificial, Heterologous | 1 | 2011 | 2 | 0.100 |
Why?
|
| Thyroid Gland | 1 | 2012 | 82 | 0.090 |
Why?
|
| Biostatistics | 1 | 2011 | 15 | 0.090 |
Why?
|
| Puerperal Infection | 1 | 2011 | 4 | 0.090 |
Why?
|
| Neoplasms, Glandular and Epithelial | 1 | 2011 | 34 | 0.090 |
Why?
|
| Lymphedema | 1 | 2011 | 20 | 0.090 |
Why?
|
| Pregnancy Complications, Neoplastic | 1 | 2011 | 50 | 0.090 |
Why?
|
| Povidone-Iodine | 1 | 2011 | 11 | 0.090 |
Why?
|
| Menarche | 2 | 2009 | 49 | 0.090 |
Why?
|
| Practice Guidelines as Topic | 2 | 2012 | 1395 | 0.090 |
Why?
|
| Disintegrins | 1 | 2011 | 5 | 0.090 |
Why?
|
| Antibiotics, Antineoplastic | 1 | 2011 | 109 | 0.090 |
Why?
|
| Prenatal Diagnosis | 1 | 2012 | 167 | 0.090 |
Why?
|
| Tissue Donors | 2 | 2011 | 316 | 0.090 |
Why?
|
| Anti-Infective Agents, Local | 1 | 2011 | 40 | 0.090 |
Why?
|
| Fallopian Tube Diseases | 3 | 2009 | 5 | 0.090 |
Why?
|
| Crime | 2 | 2014 | 59 | 0.090 |
Why?
|
| Dental Scaling | 1 | 2010 | 5 | 0.090 |
Why?
|
| Treatment Failure | 4 | 2014 | 331 | 0.090 |
Why?
|
| Angiogenic Proteins | 1 | 2010 | 18 | 0.090 |
Why?
|
| Germ-Line Mutation | 1 | 2011 | 130 | 0.090 |
Why?
|
| HIV Infections | 2 | 2019 | 2469 | 0.090 |
Why?
|
| Editorial Policies | 1 | 2011 | 45 | 0.090 |
Why?
|
| Oral Hygiene | 1 | 2010 | 18 | 0.090 |
Why?
|
| Patient-Centered Care | 1 | 2015 | 473 | 0.090 |
Why?
|
| Altitude | 1 | 2014 | 432 | 0.090 |
Why?
|
| Lymph Node Excision | 1 | 2011 | 139 | 0.090 |
Why?
|
| Chi-Square Distribution | 4 | 2017 | 493 | 0.090 |
Why?
|
| Vaginosis, Bacterial | 1 | 2010 | 11 | 0.090 |
Why?
|
| Bias | 1 | 2011 | 179 | 0.090 |
Why?
|
| Doxorubicin | 1 | 2011 | 285 | 0.090 |
Why?
|
| Triage | 1 | 2012 | 199 | 0.090 |
Why?
|
| Occupational Exposure | 2 | 2005 | 255 | 0.090 |
Why?
|
| Nicotine | 2 | 2022 | 265 | 0.090 |
Why?
|
| Oocytes | 3 | 2017 | 170 | 0.090 |
Why?
|
| Sleep | 1 | 2015 | 632 | 0.090 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2018 | 1355 | 0.090 |
Why?
|
| Abnormalities, Drug-Induced | 2 | 2000 | 10 | 0.090 |
Why?
|
| Antidepressive Agents | 1 | 2011 | 195 | 0.090 |
Why?
|
| Amenorrhea | 1 | 2010 | 27 | 0.090 |
Why?
|
| Animals | 14 | 2017 | 31706 | 0.090 |
Why?
|
| Hypoxia-Inducible Factor-Proline Dioxygenases | 1 | 2009 | 20 | 0.090 |
Why?
|
| Protein Kinase C-alpha | 1 | 2010 | 41 | 0.090 |
Why?
|
| Adipose Tissue | 1 | 2013 | 545 | 0.080 |
Why?
|
| Aromatase Inhibitors | 1 | 2010 | 49 | 0.080 |
Why?
|
| Alzheimer Disease | 1 | 2015 | 442 | 0.080 |
Why?
|
| Fas-Associated Death Domain Protein | 1 | 2009 | 8 | 0.080 |
Why?
|
| Cocaine-Related Disorders | 3 | 2008 | 107 | 0.080 |
Why?
|
| Diagnosis-Related Groups | 1 | 2009 | 26 | 0.080 |
Why?
|
| Interleukin-1 Receptor-Associated Kinases | 1 | 2009 | 20 | 0.080 |
Why?
|
| Contraceptive Agents | 2 | 2022 | 54 | 0.080 |
Why?
|
| Peritoneal Neoplasms | 1 | 2009 | 54 | 0.080 |
Why?
|
| Violence | 2 | 2003 | 202 | 0.080 |
Why?
|
| Uterine Prolapse | 1 | 2009 | 11 | 0.080 |
Why?
|
| Amino Acid Oxidoreductases | 1 | 2009 | 18 | 0.080 |
Why?
|
| Carcinoma | 1 | 2010 | 198 | 0.080 |
Why?
|
| Educational Status | 4 | 2019 | 412 | 0.080 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2017 | 1177 | 0.080 |
Why?
|
| Contraceptive Devices, Female | 1 | 2008 | 9 | 0.080 |
Why?
|
| Haplotypes | 2 | 2015 | 448 | 0.080 |
Why?
|
| Contraceptives, Oral, Combined | 1 | 2008 | 16 | 0.080 |
Why?
|
| Length of Stay | 3 | 2022 | 962 | 0.080 |
Why?
|
| Single-Blind Method | 2 | 2019 | 258 | 0.080 |
Why?
|
| Gene Frequency | 5 | 2010 | 477 | 0.080 |
Why?
|
| Tumor Necrosis Factor-alpha | 3 | 2023 | 1140 | 0.080 |
Why?
|
| Enzymes | 1 | 2009 | 62 | 0.080 |
Why?
|
| Cyclophosphamide | 1 | 2009 | 217 | 0.080 |
Why?
|
| Self Report | 3 | 2020 | 696 | 0.080 |
Why?
|
| Bacterial Infections | 1 | 2010 | 218 | 0.080 |
Why?
|
| Pinus | 1 | 2008 | 15 | 0.080 |
Why?
|
| Surgical Wound Infection | 1 | 2011 | 248 | 0.080 |
Why?
|
| Inflammation | 3 | 2023 | 2480 | 0.080 |
Why?
|
| Domestic Violence | 2 | 2017 | 41 | 0.080 |
Why?
|
| Vitis | 1 | 2008 | 38 | 0.080 |
Why?
|
| Consensus | 1 | 2010 | 537 | 0.080 |
Why?
|
| 5' Flanking Region | 1 | 2008 | 8 | 0.080 |
Why?
|
| Sarcoma | 1 | 2009 | 137 | 0.080 |
Why?
|
| Hypoxia-Inducible Factor 1, alpha Subunit | 1 | 2009 | 249 | 0.070 |
Why?
|
| Developing Countries | 2 | 2023 | 235 | 0.070 |
Why?
|
| Biomedical Research | 1 | 2014 | 585 | 0.070 |
Why?
|
| Phytotherapy | 1 | 2008 | 66 | 0.070 |
Why?
|
| Fallopian Tubes | 3 | 2019 | 29 | 0.070 |
Why?
|
| Seeds | 1 | 2008 | 75 | 0.070 |
Why?
|
| Parvoviridae Infections | 1 | 2007 | 11 | 0.070 |
Why?
|
| Activities of Daily Living | 1 | 2010 | 349 | 0.070 |
Why?
|
| Base Pairing | 1 | 2008 | 59 | 0.070 |
Why?
|
| Abortion, Threatened | 1 | 2007 | 2 | 0.070 |
Why?
|
| Nerve Regeneration | 1 | 2008 | 50 | 0.070 |
Why?
|
| Maternal Age | 4 | 2010 | 117 | 0.070 |
Why?
|
| CA-125 Antigen | 1 | 2007 | 12 | 0.070 |
Why?
|
| Extracellular Space | 1 | 2008 | 116 | 0.070 |
Why?
|
| Olfactory Pathways | 1 | 2008 | 56 | 0.070 |
Why?
|
| Affect | 3 | 2018 | 246 | 0.070 |
Why?
|
| Sequence Deletion | 1 | 2008 | 167 | 0.070 |
Why?
|
| Dependovirus | 1 | 2007 | 52 | 0.070 |
Why?
|
| Endometrium | 1 | 2007 | 60 | 0.070 |
Why?
|
| Cystic Fibrosis | 1 | 2016 | 955 | 0.070 |
Why?
|
| Olfaction Disorders | 1 | 2008 | 50 | 0.070 |
Why?
|
| Blood Glucose | 1 | 2016 | 1828 | 0.070 |
Why?
|
| Alcohol Drinking | 3 | 2009 | 651 | 0.070 |
Why?
|
| Irritable Mood | 1 | 2008 | 48 | 0.070 |
Why?
|
| Echocardiography | 2 | 2020 | 553 | 0.070 |
Why?
|
| Sexuality | 1 | 2007 | 19 | 0.070 |
Why?
|
| Observer Variation | 3 | 2016 | 296 | 0.070 |
Why?
|
| Testicular Hormones | 1 | 2006 | 9 | 0.070 |
Why?
|
| Blood Proteins | 1 | 2009 | 231 | 0.070 |
Why?
|
| Diagnostic Techniques, Obstetrical and Gynecological | 3 | 2012 | 6 | 0.070 |
Why?
|
| Diagnostic Tests, Routine | 1 | 2008 | 87 | 0.070 |
Why?
|
| Statistics as Topic | 3 | 2014 | 292 | 0.070 |
Why?
|
| Polyethylene Glycols | 1 | 2011 | 561 | 0.070 |
Why?
|
| Drug Implants | 2 | 2018 | 70 | 0.070 |
Why?
|
| Radiotherapy | 2 | 2020 | 176 | 0.070 |
Why?
|
| Personality | 1 | 2007 | 113 | 0.070 |
Why?
|
| Rural Population | 3 | 2014 | 446 | 0.070 |
Why?
|
| Walking | 1 | 2010 | 422 | 0.070 |
Why?
|
| Combined Modality Therapy | 2 | 2021 | 1121 | 0.070 |
Why?
|
| Magnetic Resonance Imaging | 4 | 2020 | 3053 | 0.070 |
Why?
|
| Salaries and Fringe Benefits | 2 | 2019 | 52 | 0.060 |
Why?
|
| Adenosine Triphosphate | 1 | 2008 | 430 | 0.060 |
Why?
|
| Nerve Growth Factors | 1 | 2005 | 71 | 0.060 |
Why?
|
| Pregnancy Complications, Hematologic | 1 | 2005 | 16 | 0.060 |
Why?
|
| Antigens, CD34 | 1 | 2005 | 89 | 0.060 |
Why?
|
| Infertility, Male | 1 | 2005 | 59 | 0.060 |
Why?
|
| Mutation | 4 | 2020 | 3346 | 0.060 |
Why?
|
| Fatty Acids, Omega-3 | 2 | 2018 | 122 | 0.060 |
Why?
|
| Brain Mapping | 2 | 2020 | 524 | 0.060 |
Why?
|
| Microtubule Proteins | 1 | 2005 | 15 | 0.060 |
Why?
|
| Estrogens, Conjugated (USP) | 1 | 2005 | 34 | 0.060 |
Why?
|
| Spermatogenesis | 1 | 2005 | 52 | 0.060 |
Why?
|
| Th1 Cells | 1 | 2005 | 123 | 0.060 |
Why?
|
| Menstruation | 1 | 2005 | 35 | 0.060 |
Why?
|
| Intensive Care Units, Neonatal | 3 | 2013 | 176 | 0.060 |
Why?
|
| Glycoproteins | 1 | 2006 | 304 | 0.060 |
Why?
|
| Mice | 7 | 2016 | 14869 | 0.060 |
Why?
|
| Anemia, Iron-Deficiency | 1 | 2005 | 53 | 0.060 |
Why?
|
| Th2 Cells | 1 | 2005 | 154 | 0.060 |
Why?
|
| Blood Cell Count | 2 | 2020 | 50 | 0.060 |
Why?
|
| Testis | 1 | 2005 | 133 | 0.060 |
Why?
|
| Efficiency | 2 | 2017 | 84 | 0.060 |
Why?
|
| Abortion, Habitual | 1 | 2004 | 2 | 0.060 |
Why?
|
| Cell Death | 1 | 2005 | 323 | 0.060 |
Why?
|
| Astrocytes | 1 | 2005 | 162 | 0.060 |
Why?
|
| Chorionic Villi | 1 | 2004 | 16 | 0.060 |
Why?
|
| Oligodendroglia | 1 | 2005 | 148 | 0.060 |
Why?
|
| Microtubule-Associated Proteins | 1 | 2005 | 174 | 0.060 |
Why?
|
| Obstetrics | 2 | 2018 | 146 | 0.060 |
Why?
|
| Epigenesis, Genetic | 1 | 2008 | 520 | 0.060 |
Why?
|
| Bolivia | 1 | 2023 | 62 | 0.060 |
Why?
|
| DNA Methylation | 1 | 2008 | 495 | 0.050 |
Why?
|
| Thrombophilia | 1 | 2004 | 67 | 0.050 |
Why?
|
| Random Allocation | 2 | 2020 | 335 | 0.050 |
Why?
|
| Energy Metabolism | 1 | 2008 | 731 | 0.050 |
Why?
|
| Vasomotor System | 1 | 2003 | 39 | 0.050 |
Why?
|
| Probability | 3 | 2010 | 289 | 0.050 |
Why?
|
| Superoxides | 1 | 2004 | 214 | 0.050 |
Why?
|
| Pain Measurement | 2 | 2016 | 444 | 0.050 |
Why?
|
| Women | 1 | 2003 | 51 | 0.050 |
Why?
|
| Injections, Intramuscular | 1 | 2003 | 116 | 0.050 |
Why?
|
| Recurrence | 3 | 2014 | 935 | 0.050 |
Why?
|
| Health Behavior | 2 | 2010 | 704 | 0.050 |
Why?
|
| Acoustics | 1 | 2022 | 46 | 0.050 |
Why?
|
| Food Preferences | 1 | 2003 | 108 | 0.050 |
Why?
|
| Vitamins | 1 | 2023 | 151 | 0.050 |
Why?
|
| Cell Count | 2 | 2014 | 303 | 0.050 |
Why?
|
| Crime Victims | 1 | 2003 | 80 | 0.050 |
Why?
|
| Epilepsy, Temporal Lobe | 1 | 2001 | 20 | 0.050 |
Why?
|
| Cerebrospinal Fluid Leak | 1 | 2022 | 28 | 0.050 |
Why?
|
| Adaptation, Psychological | 2 | 2016 | 547 | 0.050 |
Why?
|
| Phosphoproteins | 1 | 2004 | 298 | 0.050 |
Why?
|
| Registries | 1 | 2009 | 1768 | 0.050 |
Why?
|
| Estrogens, Non-Steroidal | 1 | 2001 | 5 | 0.050 |
Why?
|
| United Kingdom | 2 | 2014 | 226 | 0.050 |
Why?
|
| Matrix Metalloproteinase 9 | 1 | 2002 | 119 | 0.050 |
Why?
|
| Lipids | 2 | 2009 | 580 | 0.050 |
Why?
|
| Drug Therapy, Combination | 2 | 2020 | 951 | 0.050 |
Why?
|
| Amniotic Fluid | 1 | 2001 | 64 | 0.050 |
Why?
|
| Culture | 2 | 2012 | 124 | 0.050 |
Why?
|
| Infant Food | 1 | 2001 | 63 | 0.050 |
Why?
|
| Postoperative Period | 1 | 2022 | 289 | 0.050 |
Why?
|
| Fatigue | 1 | 2022 | 294 | 0.050 |
Why?
|
| Elective Surgical Procedures | 1 | 2022 | 151 | 0.050 |
Why?
|
| Reward | 1 | 2023 | 211 | 0.050 |
Why?
|
| Fibrinolytic Agents | 1 | 2023 | 234 | 0.050 |
Why?
|
| Patient Selection | 3 | 2014 | 641 | 0.040 |
Why?
|
| Confidence Intervals | 2 | 2012 | 305 | 0.040 |
Why?
|
| Emergency Treatment | 1 | 2021 | 113 | 0.040 |
Why?
|
| Gene Expression Regulation, Enzymologic | 1 | 2001 | 270 | 0.040 |
Why?
|
| Salpingo-oophorectomy | 1 | 2020 | 11 | 0.040 |
Why?
|
| Prescriptions | 1 | 2020 | 60 | 0.040 |
Why?
|
| Diagnostic Errors | 2 | 2012 | 149 | 0.040 |
Why?
|
| Semen | 1 | 2000 | 18 | 0.040 |
Why?
|
| Diet | 2 | 2018 | 1080 | 0.040 |
Why?
|
| Interpersonal Relations | 1 | 2003 | 341 | 0.040 |
Why?
|
| Cytochrome P-450 CYP3A | 2 | 2012 | 61 | 0.040 |
Why?
|
| Ibuprofen | 1 | 2020 | 75 | 0.040 |
Why?
|
| Cues | 1 | 2022 | 300 | 0.040 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 1 | 2005 | 520 | 0.040 |
Why?
|
| BRCA1 Protein | 1 | 2020 | 56 | 0.040 |
Why?
|
| Cervical Length Measurement | 1 | 2019 | 2 | 0.040 |
Why?
|
| Infant | 3 | 2023 | 7963 | 0.040 |
Why?
|
| Ovariectomy | 1 | 2020 | 116 | 0.040 |
Why?
|
| Dried Blood Spot Testing | 1 | 2020 | 71 | 0.040 |
Why?
|
| Pesticides | 1 | 2000 | 49 | 0.040 |
Why?
|
| Women's Health Services | 1 | 2000 | 15 | 0.040 |
Why?
|
| Phentermine | 1 | 1999 | 8 | 0.040 |
Why?
|
| Behavior | 1 | 2020 | 92 | 0.040 |
Why?
|
| Pressure | 1 | 2020 | 214 | 0.040 |
Why?
|
| Fenfluramine | 1 | 1999 | 13 | 0.040 |
Why?
|
| Fingers | 1 | 2000 | 83 | 0.040 |
Why?
|
| Appetite Depressants | 1 | 1999 | 18 | 0.040 |
Why?
|
| Aneuploidy | 1 | 2020 | 85 | 0.040 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 2 | 2016 | 797 | 0.040 |
Why?
|
| Cells, Cultured | 4 | 2009 | 3886 | 0.040 |
Why?
|
| Cost-Benefit Analysis | 2 | 2014 | 544 | 0.040 |
Why?
|
| Forecasting | 1 | 2021 | 330 | 0.040 |
Why?
|
| Heart Valves | 1 | 1999 | 41 | 0.040 |
Why?
|
| Endometritis | 1 | 2019 | 4 | 0.040 |
Why?
|
| Epidemiologic Methods | 1 | 1999 | 72 | 0.040 |
Why?
|
| Pregnancy Trimester, Third | 1 | 2019 | 79 | 0.040 |
Why?
|
| Sterilization, Reproductive | 1 | 2018 | 6 | 0.040 |
Why?
|
| Disease-Free Survival | 2 | 2011 | 620 | 0.040 |
Why?
|
| Histones | 1 | 2004 | 535 | 0.040 |
Why?
|
| Polymorphism, Genetic | 1 | 2002 | 610 | 0.040 |
Why?
|
| Pain, Postoperative | 1 | 2020 | 191 | 0.040 |
Why?
|
| Authorship | 1 | 2019 | 31 | 0.040 |
Why?
|
| Electronic Mail | 1 | 2019 | 54 | 0.040 |
Why?
|
| Chemoradiotherapy | 1 | 2020 | 188 | 0.040 |
Why?
|
| Transportation | 1 | 2019 | 44 | 0.040 |
Why?
|
| Rupture | 1 | 2019 | 96 | 0.040 |
Why?
|
| Videoconferencing | 1 | 2019 | 57 | 0.040 |
Why?
|
| Neural Pathways | 1 | 2020 | 261 | 0.040 |
Why?
|
| Long-Acting Reversible Contraception | 1 | 2018 | 24 | 0.040 |
Why?
|
| Anxiety Disorders | 1 | 2021 | 303 | 0.040 |
Why?
|
| Health Communication | 1 | 2019 | 40 | 0.040 |
Why?
|
| Neutrophils | 1 | 2004 | 1176 | 0.040 |
Why?
|
| Neuronal Plasticity | 1 | 2020 | 209 | 0.040 |
Why?
|
| Genotype | 3 | 2010 | 1760 | 0.040 |
Why?
|
| Fatty Acids, Unsaturated | 1 | 2018 | 84 | 0.040 |
Why?
|
| Chemical Industry | 1 | 1998 | 9 | 0.040 |
Why?
|
| Petroleum | 1 | 1998 | 5 | 0.040 |
Why?
|
| Placebos | 2 | 2014 | 197 | 0.040 |
Why?
|
| Emotions | 1 | 2022 | 472 | 0.040 |
Why?
|
| Laparotomy | 1 | 2018 | 103 | 0.040 |
Why?
|
| Limit of Detection | 1 | 2018 | 53 | 0.040 |
Why?
|
| Kaplan-Meier Estimate | 2 | 2011 | 811 | 0.040 |
Why?
|
| Intraoperative Complications | 1 | 2019 | 122 | 0.040 |
Why?
|
| Primary Health Care | 1 | 2007 | 1513 | 0.040 |
Why?
|
| Hysterectomy, Vaginal | 1 | 2017 | 3 | 0.040 |
Why?
|
| Parents | 1 | 2005 | 1186 | 0.040 |
Why?
|
| Visually Impaired Persons | 1 | 2017 | 6 | 0.040 |
Why?
|
| California | 1 | 2019 | 353 | 0.040 |
Why?
|
| Sex Factors | 2 | 2016 | 1715 | 0.040 |
Why?
|
| Nomograms | 1 | 2017 | 41 | 0.040 |
Why?
|
| Heart Valve Diseases | 1 | 1999 | 161 | 0.040 |
Why?
|
| Mother-Child Relations | 1 | 2018 | 111 | 0.040 |
Why?
|
| Device Approval | 1 | 2017 | 21 | 0.040 |
Why?
|
| Health Expenditures | 1 | 2019 | 171 | 0.040 |
Why?
|
| Luteal Phase | 2 | 2009 | 41 | 0.040 |
Why?
|
| Patient Health Questionnaire | 1 | 2017 | 21 | 0.040 |
Why?
|
| Work-Life Balance | 1 | 2017 | 10 | 0.040 |
Why?
|
| Placebo Effect | 1 | 2017 | 52 | 0.030 |
Why?
|
| Statistics, Nonparametric | 2 | 2010 | 385 | 0.030 |
Why?
|
| Ambulatory Care Facilities | 1 | 2019 | 213 | 0.030 |
Why?
|
| Child of Impaired Parents | 1 | 2017 | 40 | 0.030 |
Why?
|
| Perinatal Care | 1 | 2017 | 36 | 0.030 |
Why?
|
| Principal Component Analysis | 1 | 2017 | 175 | 0.030 |
Why?
|
| Family Conflict | 1 | 2017 | 36 | 0.030 |
Why?
|
| Contraceptives, Oral | 1 | 2016 | 25 | 0.030 |
Why?
|
| Diabetes Mellitus | 2 | 2019 | 900 | 0.030 |
Why?
|
| Paraventricular Hypothalamic Nucleus | 1 | 2016 | 23 | 0.030 |
Why?
|
| Decision Trees | 2 | 2008 | 81 | 0.030 |
Why?
|
| Physicians, Family | 1 | 2018 | 201 | 0.030 |
Why?
|
| Heterozygote | 1 | 2017 | 251 | 0.030 |
Why?
|
| RNA, Ribosomal, 16S | 1 | 2018 | 485 | 0.030 |
Why?
|
| Interleukin-1beta | 1 | 2018 | 370 | 0.030 |
Why?
|
| Radioimmunoassay | 2 | 2007 | 162 | 0.030 |
Why?
|
| Feces | 1 | 2018 | 373 | 0.030 |
Why?
|
| Diet Records | 1 | 2016 | 76 | 0.030 |
Why?
|
| Directive Counseling | 1 | 2016 | 41 | 0.030 |
Why?
|
| Occupational Diseases | 1 | 1998 | 128 | 0.030 |
Why?
|
| Blood Transfusion | 1 | 2019 | 293 | 0.030 |
Why?
|
| Reoperation | 1 | 2018 | 514 | 0.030 |
Why?
|
| Genetic Markers | 1 | 2017 | 320 | 0.030 |
Why?
|
| Transcription Factors | 1 | 2004 | 1528 | 0.030 |
Why?
|
| Muscle, Skeletal | 1 | 2005 | 1473 | 0.030 |
Why?
|
| Survival Rate | 1 | 2020 | 1644 | 0.030 |
Why?
|
| Age Distribution | 2 | 2008 | 342 | 0.030 |
Why?
|
| Condoms | 1 | 2016 | 113 | 0.030 |
Why?
|
| Feedback | 1 | 2016 | 144 | 0.030 |
Why?
|
| Prefrontal Cortex | 1 | 2018 | 262 | 0.030 |
Why?
|
| Vitamin D | 1 | 2019 | 341 | 0.030 |
Why?
|
| Epilepsy | 1 | 1999 | 278 | 0.030 |
Why?
|
| Organ Size | 1 | 2016 | 436 | 0.030 |
Why?
|
| Wounds and Injuries | 2 | 2000 | 749 | 0.030 |
Why?
|
| Corticosterone | 1 | 2016 | 211 | 0.030 |
Why?
|
| Telephone | 1 | 2016 | 152 | 0.030 |
Why?
|
| Plant Preparations | 2 | 2008 | 23 | 0.030 |
Why?
|
| Serotonin | 1 | 2017 | 292 | 0.030 |
Why?
|
| Insurance, Health | 1 | 2017 | 244 | 0.030 |
Why?
|
| Animals, Newborn | 1 | 2017 | 778 | 0.030 |
Why?
|
| Health Care Surveys | 1 | 2017 | 539 | 0.030 |
Why?
|
| Spatial Memory | 1 | 2015 | 17 | 0.030 |
Why?
|
| Erythrocytes | 1 | 2020 | 591 | 0.030 |
Why?
|
| Propensity Score | 1 | 2016 | 224 | 0.030 |
Why?
|
| Glucose Tolerance Test | 1 | 2016 | 343 | 0.030 |
Why?
|
| Wechsler Scales | 1 | 2015 | 52 | 0.030 |
Why?
|
| Labor, Obstetric | 2 | 2005 | 52 | 0.030 |
Why?
|
| Apolipoprotein E4 | 1 | 2015 | 32 | 0.030 |
Why?
|
| Hospitalization | 2 | 2019 | 1752 | 0.030 |
Why?
|
| Gene Expression Regulation | 1 | 2004 | 2320 | 0.030 |
Why?
|
| Health Literacy | 1 | 2017 | 164 | 0.030 |
Why?
|
| Fetal Distress | 1 | 2014 | 12 | 0.030 |
Why?
|
| Down-Regulation | 1 | 2017 | 594 | 0.030 |
Why?
|
| Dietary Supplements | 2 | 2014 | 460 | 0.030 |
Why?
|
| Personality Inventory | 2 | 2006 | 131 | 0.030 |
Why?
|
| Leisure Activities | 1 | 2014 | 25 | 0.030 |
Why?
|
| Sex Characteristics | 1 | 2019 | 641 | 0.030 |
Why?
|
| Lost to Follow-Up | 1 | 2014 | 22 | 0.030 |
Why?
|
| Behavior, Animal | 1 | 2017 | 458 | 0.030 |
Why?
|
| Placenta Growth Factor | 1 | 2014 | 22 | 0.030 |
Why?
|
| Age of Onset | 1 | 2015 | 446 | 0.030 |
Why?
|
| Symptom Assessment | 1 | 2015 | 119 | 0.030 |
Why?
|
| Venlafaxine Hydrochloride | 1 | 2014 | 11 | 0.030 |
Why?
|
| Point-of-Care Systems | 1 | 2015 | 136 | 0.030 |
Why?
|
| Cyclohexanols | 1 | 2014 | 9 | 0.030 |
Why?
|
| Heparin | 1 | 2015 | 224 | 0.030 |
Why?
|
| Mental Recall | 1 | 2015 | 171 | 0.030 |
Why?
|
| Patient Readmission | 1 | 2019 | 610 | 0.030 |
Why?
|
| Health | 1 | 2014 | 74 | 0.030 |
Why?
|
| International Classification of Diseases | 1 | 2014 | 116 | 0.030 |
Why?
|
| Checklist | 1 | 2014 | 83 | 0.030 |
Why?
|
| Yoga | 1 | 2014 | 28 | 0.030 |
Why?
|
| Gonadotropins, Pituitary | 1 | 2013 | 22 | 0.030 |
Why?
|
| Self Efficacy | 1 | 2017 | 355 | 0.030 |
Why?
|
| Delayed Diagnosis | 1 | 2014 | 70 | 0.030 |
Why?
|
| Quality Control | 1 | 2014 | 144 | 0.030 |
Why?
|
| Mice, Inbred C57BL | 2 | 2016 | 4694 | 0.030 |
Why?
|
| Income | 1 | 2014 | 167 | 0.030 |
Why?
|
| Health Personnel | 1 | 2019 | 574 | 0.030 |
Why?
|
| Uterine Artery | 1 | 2014 | 67 | 0.030 |
Why?
|
| Medicaid | 1 | 2017 | 407 | 0.030 |
Why?
|
| Coronary Artery Disease | 1 | 1999 | 607 | 0.030 |
Why?
|
| Agriculture | 1 | 2013 | 72 | 0.030 |
Why?
|
| Up-Regulation | 1 | 2016 | 808 | 0.030 |
Why?
|
| Cross-Cultural Comparison | 2 | 2005 | 77 | 0.030 |
Why?
|
| Genetic Predisposition to Disease | 3 | 2010 | 2086 | 0.030 |
Why?
|
| Alleles | 2 | 2006 | 789 | 0.030 |
Why?
|
| Follicular Atresia | 1 | 2012 | 4 | 0.030 |
Why?
|
| Hospital Units | 1 | 2012 | 23 | 0.030 |
Why?
|
| Birth Rate | 1 | 2012 | 19 | 0.030 |
Why?
|
| Micromanipulation | 1 | 2012 | 12 | 0.030 |
Why?
|
| Cytochrome P-450 CYP1B1 | 1 | 2012 | 5 | 0.030 |
Why?
|
| Microbiota | 1 | 2019 | 647 | 0.030 |
Why?
|
| Heart Rate | 1 | 2016 | 709 | 0.030 |
Why?
|
| Sexism | 1 | 2012 | 44 | 0.020 |
Why?
|
| Thyroxine-Binding Globulin | 1 | 2012 | 1 | 0.020 |
Why?
|
| Psychometrics | 2 | 2008 | 608 | 0.020 |
Why?
|
| Motivation | 1 | 2016 | 494 | 0.020 |
Why?
|
| Patient Admission | 1 | 2013 | 176 | 0.020 |
Why?
|
| Triiodothyronine | 1 | 2012 | 42 | 0.020 |
Why?
|
| Comparative Effectiveness Research | 1 | 2012 | 130 | 0.020 |
Why?
|
| Thyroxine | 1 | 2012 | 56 | 0.020 |
Why?
|
| Organizational Culture | 1 | 2012 | 119 | 0.020 |
Why?
|
| Thyrotropin | 1 | 2012 | 99 | 0.020 |
Why?
|
| Feasibility Studies | 1 | 2014 | 740 | 0.020 |
Why?
|
| Semen Preservation | 1 | 2011 | 3 | 0.020 |
Why?
|
| Semen Analysis | 1 | 2011 | 10 | 0.020 |
Why?
|
| Clomiphene | 1 | 2011 | 15 | 0.020 |
Why?
|
| Dosage Forms | 1 | 2011 | 10 | 0.020 |
Why?
|
| Estrogens | 1 | 2014 | 312 | 0.020 |
Why?
|
| Matrix Metalloproteinase 12 | 1 | 2011 | 7 | 0.020 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 2 | 2004 | 923 | 0.020 |
Why?
|
| Base Sequence | 2 | 2005 | 2114 | 0.020 |
Why?
|
| Endoglin | 1 | 2010 | 20 | 0.020 |
Why?
|
| Social Environment | 1 | 2012 | 283 | 0.020 |
Why?
|
| Arylsulfotransferase | 1 | 2010 | 3 | 0.020 |
Why?
|
| Sulfotransferases | 1 | 2010 | 6 | 0.020 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 1 | 2013 | 238 | 0.020 |
Why?
|
| Child, Preschool | 3 | 2017 | 9116 | 0.020 |
Why?
|
| Metabolic Equivalent | 1 | 2010 | 3 | 0.020 |
Why?
|
| Waist-Hip Ratio | 1 | 2010 | 30 | 0.020 |
Why?
|
| New England | 1 | 2010 | 27 | 0.020 |
Why?
|
| Remission Induction | 1 | 2011 | 233 | 0.020 |
Why?
|
| Exercise Therapy | 1 | 2014 | 352 | 0.020 |
Why?
|
| Molecular Sequence Data | 2 | 2005 | 2785 | 0.020 |
Why?
|
| Gene Expression Profiling | 1 | 2016 | 1518 | 0.020 |
Why?
|
| Waist Circumference | 1 | 2010 | 122 | 0.020 |
Why?
|
| Chronic Disease | 2 | 2007 | 1578 | 0.020 |
Why?
|
| Vaginal Smears | 1 | 2010 | 50 | 0.020 |
Why?
|
| Sperm Count | 1 | 2009 | 16 | 0.020 |
Why?
|
| Tocolytic Agents | 1 | 2009 | 15 | 0.020 |
Why?
|
| Dementia | 1 | 2012 | 187 | 0.020 |
Why?
|
| Spouse Abuse | 2 | 2000 | 36 | 0.020 |
Why?
|
| Magnesium Sulfate | 1 | 2009 | 16 | 0.020 |
Why?
|
| Oxidoreductases, N-Demethylating | 1 | 2009 | 10 | 0.020 |
Why?
|
| Glutathione S-Transferase pi | 1 | 2009 | 8 | 0.020 |
Why?
|
| Cytochrome P-450 CYP2B6 | 1 | 2009 | 9 | 0.020 |
Why?
|
| Emergency Medical Services | 2 | 2011 | 590 | 0.020 |
Why?
|
| Tissue Array Analysis | 1 | 2009 | 48 | 0.020 |
Why?
|
| Fetal Death | 1 | 2009 | 50 | 0.020 |
Why?
|
| Respiratory Distress Syndrome, Newborn | 1 | 2010 | 101 | 0.020 |
Why?
|
| Social Support | 1 | 2012 | 528 | 0.020 |
Why?
|
| Tamoxifen | 1 | 2010 | 191 | 0.020 |
Why?
|
| Glutathione Transferase | 1 | 2009 | 93 | 0.020 |
Why?
|
| Pelvic Floor | 1 | 2009 | 22 | 0.020 |
Why?
|
| Evaluation Studies as Topic | 1 | 2009 | 167 | 0.020 |
Why?
|
| Ethinyl Estradiol | 1 | 2008 | 17 | 0.020 |
Why?
|
| Cell Hypoxia | 1 | 2009 | 221 | 0.020 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 2010 | 332 | 0.020 |
Why?
|
| Long-Term Care | 1 | 2009 | 78 | 0.020 |
Why?
|
| Receptors, Cell Surface | 1 | 2010 | 355 | 0.020 |
Why?
|
| False Positive Reactions | 1 | 2008 | 109 | 0.020 |
Why?
|
| Plant Bark | 1 | 2008 | 11 | 0.020 |
Why?
|
| China | 2 | 2000 | 161 | 0.020 |
Why?
|
| Evidence-Based Medicine | 1 | 2012 | 668 | 0.020 |
Why?
|
| Sample Size | 1 | 2008 | 112 | 0.020 |
Why?
|
| Administration, Cutaneous | 1 | 2008 | 117 | 0.020 |
Why?
|
| Acrosome | 1 | 2008 | 4 | 0.020 |
Why?
|
| Drug Costs | 1 | 2009 | 92 | 0.020 |
Why?
|
| Analysis of Variance | 2 | 2002 | 1226 | 0.020 |
Why?
|
| Minerals | 1 | 2008 | 37 | 0.020 |
Why?
|
| Global Health | 1 | 2010 | 287 | 0.020 |
Why?
|
| Sperm Capacitation | 1 | 2008 | 12 | 0.020 |
Why?
|
| Antigens, CD | 1 | 2010 | 442 | 0.020 |
Why?
|
| Proteins | 1 | 2014 | 908 | 0.020 |
Why?
|
| Neurotic Disorders | 1 | 2007 | 7 | 0.020 |
Why?
|
| Electronic Health Records | 1 | 2014 | 800 | 0.020 |
Why?
|
| Drug Combinations | 1 | 2008 | 287 | 0.020 |
Why?
|
| Macrophage Migration-Inhibitory Factors | 1 | 2007 | 10 | 0.020 |
Why?
|
| Mothers | 1 | 2013 | 651 | 0.020 |
Why?
|
| Personality Assessment | 1 | 2007 | 77 | 0.020 |
Why?
|
| Body Weights and Measures | 1 | 2007 | 34 | 0.020 |
Why?
|
| Olfactory Mucosa | 1 | 2008 | 60 | 0.020 |
Why?
|
| Neurologic Examination | 1 | 2008 | 114 | 0.020 |
Why?
|
| Cell Line | 2 | 2004 | 2637 | 0.020 |
Why?
|
| Spleen | 1 | 2009 | 487 | 0.020 |
Why?
|
| Sexually Transmitted Diseases, Bacterial | 1 | 2007 | 1 | 0.020 |
Why?
|
| Chromatin Immunoprecipitation | 1 | 2008 | 128 | 0.020 |
Why?
|
| Transcription, Genetic | 2 | 2005 | 1313 | 0.020 |
Why?
|
| Drug Evaluation, Preclinical | 1 | 2008 | 161 | 0.020 |
Why?
|
| Energy Intake | 1 | 2010 | 427 | 0.020 |
Why?
|
| Androsterone | 1 | 2007 | 2 | 0.020 |
Why?
|
| Mice, Inbred Strains | 1 | 2008 | 396 | 0.020 |
Why?
|
| Intramolecular Oxidoreductases | 1 | 2007 | 57 | 0.020 |
Why?
|
| Stillbirth | 1 | 2007 | 57 | 0.020 |
Why?
|
| Mutation, Missense | 1 | 2009 | 293 | 0.020 |
Why?
|
| Tyrosine | 1 | 2008 | 214 | 0.020 |
Why?
|
| Chemokine CCL2 | 1 | 2007 | 105 | 0.020 |
Why?
|
| Psychological Tests | 1 | 2008 | 120 | 0.020 |
Why?
|
| Sexual Partners | 1 | 2008 | 161 | 0.020 |
Why?
|
| Arthralgia | 1 | 2007 | 46 | 0.020 |
Why?
|
| Health Status Indicators | 1 | 2008 | 156 | 0.020 |
Why?
|
| Outpatients | 1 | 2010 | 326 | 0.020 |
Why?
|
| Adenoviridae | 1 | 2007 | 184 | 0.020 |
Why?
|
| Streptococcus agalactiae | 1 | 2008 | 81 | 0.020 |
Why?
|
| Cytomegalovirus | 1 | 2007 | 144 | 0.020 |
Why?
|
| Body Height | 1 | 2007 | 180 | 0.020 |
Why?
|
| Genetic Testing | 1 | 2009 | 381 | 0.020 |
Why?
|
| Immunoglobulin M | 1 | 2007 | 246 | 0.020 |
Why?
|
| Calcium Signaling | 1 | 2008 | 217 | 0.020 |
Why?
|
| Leptin | 1 | 2007 | 210 | 0.020 |
Why?
|
| Streptococcal Infections | 1 | 2008 | 131 | 0.020 |
Why?
|
| Reproductive History | 1 | 2005 | 12 | 0.020 |
Why?
|
| Mass Screening | 1 | 2012 | 1004 | 0.020 |
Why?
|
| Osmolar Concentration | 1 | 2006 | 173 | 0.020 |
Why?
|
| Hematopoietic Stem Cell Mobilization | 1 | 2005 | 20 | 0.020 |
Why?
|
| Respiration, Artificial | 1 | 2009 | 529 | 0.020 |
Why?
|
| Androstenedione | 1 | 2005 | 10 | 0.020 |
Why?
|
| Attitude of Health Personnel | 1 | 2012 | 975 | 0.020 |
Why?
|
| Sperm Tail | 1 | 2005 | 5 | 0.020 |
Why?
|
| Sleep Apnea, Obstructive | 1 | 2008 | 196 | 0.020 |
Why?
|
| Immunohistochemistry | 1 | 2009 | 1629 | 0.020 |
Why?
|
| Glucocorticoids | 1 | 2009 | 532 | 0.020 |
Why?
|
| U937 Cells | 1 | 2004 | 22 | 0.010 |
Why?
|
| Protein-Tyrosine Kinases | 1 | 2008 | 395 | 0.010 |
Why?
|
| Mice, SCID | 1 | 2005 | 314 | 0.010 |
Why?
|
| Sequence Homology, Nucleic Acid | 1 | 2004 | 152 | 0.010 |
Why?
|
| Safety | 1 | 2006 | 297 | 0.010 |
Why?
|
| Physicians | 1 | 2012 | 772 | 0.010 |
Why?
|
| Electrophoretic Mobility Shift Assay | 1 | 2004 | 72 | 0.010 |
Why?
|
| Luciferases | 1 | 2004 | 142 | 0.010 |
Why?
|
| Prothrombin | 1 | 2004 | 22 | 0.010 |
Why?
|
| Steroidogenic Factor 1 | 1 | 2004 | 6 | 0.010 |
Why?
|
| Leydig Cells | 1 | 2004 | 11 | 0.010 |
Why?
|
| Tissue Polypeptide Antigen | 1 | 2004 | 2 | 0.010 |
Why?
|
| 8-Bromo Cyclic Adenosine Monophosphate | 1 | 2004 | 17 | 0.010 |
Why?
|
| Membranes | 1 | 2004 | 18 | 0.010 |
Why?
|
| Protein Array Analysis | 1 | 2004 | 56 | 0.010 |
Why?
|
| Interferon-gamma | 1 | 2007 | 719 | 0.010 |
Why?
|
| Granulosa Cells | 1 | 2004 | 29 | 0.010 |
Why?
|
| Phosphorylation | 1 | 2008 | 1569 | 0.010 |
Why?
|
| Mice, Inbred NOD | 1 | 2005 | 555 | 0.010 |
Why?
|
| Immunoglobulin G | 1 | 2007 | 770 | 0.010 |
Why?
|
| Stem Cells | 1 | 2008 | 546 | 0.010 |
Why?
|
| Midwestern United States | 1 | 2003 | 38 | 0.010 |
Why?
|
| Psychology | 1 | 2004 | 82 | 0.010 |
Why?
|
| Chromosome Mapping | 1 | 2004 | 487 | 0.010 |
Why?
|
| Coculture Techniques | 1 | 2004 | 201 | 0.010 |
Why?
|
| Body Weight | 1 | 2007 | 869 | 0.010 |
Why?
|
| Hemorrhage | 1 | 2007 | 620 | 0.010 |
Why?
|
| Fibroblasts | 1 | 2008 | 838 | 0.010 |
Why?
|
| Alternative Splicing | 1 | 2004 | 187 | 0.010 |
Why?
|
| Demography | 1 | 2003 | 260 | 0.010 |
Why?
|
| Gonorrhea | 1 | 2003 | 54 | 0.010 |
Why?
|
| DNA Mutational Analysis | 1 | 2004 | 372 | 0.010 |
Why?
|
| Hematopoietic Stem Cells | 1 | 2005 | 343 | 0.010 |
Why?
|
| Tandem Repeat Sequences | 1 | 2002 | 17 | 0.010 |
Why?
|
| Muscle Contraction | 1 | 2005 | 389 | 0.010 |
Why?
|
| Extraembryonic Membranes | 1 | 2001 | 4 | 0.010 |
Why?
|
| Flow Cytometry | 1 | 2005 | 1083 | 0.010 |
Why?
|
| Isoflavones | 1 | 2001 | 16 | 0.010 |
Why?
|
| Phytoestrogens | 1 | 2001 | 13 | 0.010 |
Why?
|
| Substance-Related Disorders | 2 | 2000 | 947 | 0.010 |
Why?
|
| Vascular Endothelial Growth Factor A | 1 | 2004 | 498 | 0.010 |
Why?
|
| National Institutes of Health (U.S.) | 1 | 2002 | 106 | 0.010 |
Why?
|
| Gene Expression | 1 | 2006 | 1421 | 0.010 |
Why?
|
| Genes, Reporter | 1 | 2001 | 257 | 0.010 |
Why?
|
| Patient Participation | 1 | 2004 | 359 | 0.010 |
Why?
|
| Body Constitution | 1 | 2001 | 47 | 0.010 |
Why?
|
| Mass Spectrometry | 1 | 2004 | 633 | 0.010 |
Why?
|
| Acute Disease | 1 | 2003 | 911 | 0.010 |
Why?
|
| DNA Primers | 1 | 2001 | 510 | 0.010 |
Why?
|
| Disease Models, Animal | 1 | 2009 | 3535 | 0.010 |
Why?
|
| Neurons | 1 | 2008 | 1280 | 0.010 |
Why?
|
| Tumor Cells, Cultured | 1 | 2001 | 849 | 0.010 |
Why?
|
| Models, Neurological | 1 | 2001 | 212 | 0.010 |
Why?
|
| Infant Nutritional Physiological Phenomena | 1 | 2001 | 133 | 0.010 |
Why?
|
| Apolipoprotein A-I | 1 | 1999 | 25 | 0.010 |
Why?
|
| North Dakota | 1 | 1999 | 6 | 0.010 |
Why?
|
| Apolipoproteins B | 1 | 1999 | 41 | 0.010 |
Why?
|
| Hypertension | 1 | 2007 | 1056 | 0.010 |
Why?
|
| Transfection | 1 | 2001 | 866 | 0.010 |
Why?
|
| Lipoproteins, HDL | 1 | 1999 | 75 | 0.010 |
Why?
|
| Lipoprotein(a) | 1 | 1999 | 51 | 0.010 |
Why?
|
| Lipoproteins, LDL | 1 | 1999 | 128 | 0.010 |
Why?
|
| Risk | 1 | 2001 | 812 | 0.010 |
Why?
|
| Benzene | 1 | 1998 | 13 | 0.010 |
Why?
|
| Cholesterol | 1 | 1999 | 367 | 0.010 |
Why?
|
| Population Surveillance | 1 | 2001 | 392 | 0.010 |
Why?
|
| Hydrogen Sulfide | 1 | 1998 | 40 | 0.010 |
Why?
|
| Bone and Bones | 1 | 2000 | 279 | 0.010 |
Why?
|
| Health Policy | 1 | 2000 | 334 | 0.010 |
Why?
|
| Epithelial Cells | 1 | 2002 | 951 | 0.010 |
Why?
|
| Maternal Exposure | 1 | 1998 | 138 | 0.010 |
Why?
|
| Melanoma | 1 | 2001 | 620 | 0.010 |
Why?
|